44 results about "Cell surface receptor" patented technology

The invention discloses injection type facial filler composition gel for medical beauty as well as a preparation method and application of the injection type facial filler composition gel, and belongs to the technical field of biomedical materials. The composition gel comprises a combined gel matrix and polycaprolactone microspheres, wherein the combined gel matrix comprises an aqueous solution for injection, sodium carboxymethyl cellulose and human recombinant collagen; according to the composition gel, a combined gel matrix and polycaprolactone microspheres are mixed according to a specific proportion, amino acid residues of human-derived recombinant collagen in the combined gel matrix serve as binding sites of cell surface receptors to improve the cell recognition and attachment capacity of the polycaprolactone microspheres, and the amino acid residues are organically combined with sodium carboxymethyl cellulose to improve the cell recognition and attachment capacity of the polycaprolactone microspheres. The durability and biocompatibility of the shaping effect of the human-derived recombinant collagen at the injection site are improved; the composition prepared by the invention is good in gel fluidity, high in elastic modulus and high in dynamic viscosity, and can meet the expected mechanical and rheological properties of a facial filling agent for cosmetic and plastic surgery.

The invention discloses a bispecific bridging body, the bridging body contains an xPD1 fragment capable of being specifically combined with PD-L1 molecules on the surface of a tumor cell with high affinity and a CD16A scFv fragment capable of specifically recognizing a CD16A receptor on the surface of an NK cell, a nucleotide sequence for coding the xPD1 fragment is shown as SEQ ID NO.1, and a nucleotide sequence for coding the CD16A scFv fragment is shown as SEQ ID NO.3. The invention further discloses a preparation method of the bispecific bridging body. The targeting recognition precision of the NK cells on tumor cells is remarkably improved, invalid migration of the NK cells in vivo is avoided, and the killing activity of the NK cells can be enhanced through the synergistic effect of CD16A receptor aggregation activation and PD-L1 pathway blocking.

The invention discloses a low-sensitivity whitening recombinant humanized collagen composition and a preparation method thereof. The low-sensitivity whitening recombinant humanized collagen composition is prepared from modified recombinant humanized collagen, tetrahydrocurcumin, ethyl ascorbic acid ether and dipotassium glycyrrhizinate, the modified recombinant humanized collagen comprises a recombinant humanized collagen chain segment, a polyethylene glycol chain segment modified on the recombinant humanized collagen chain segment, and tetrahydromethyl pyrimidine formyl modified at the other end of the polyethylene glycol chain segment. The modified recombinant humanized collagen can provide proper steric hindrance to achieve the effects of shielding residual antigen epitopes and improving the efficiency of combining target spot cell surface receptors, and cooperates with other mild whitening components to act on various pathways (including oxidation resistance, transport inhibition, enzyme inhibition and inflammation resistance), so that synergistic interaction and irritant hedging are realized, and the skin whitening effect is improved. Therefore, the whitening effect is achieved under low skin irritation.

The present disclosure relates to engineered IgG molecules having an IgM Cµ2 domain substituted for all or a portion of an IgG hinge region. Engineered IgG molecules may include one or more targeting moieties that are capable of agonizing a cell surface receptor and may be used, for example, in methods of agonizing certain receptors.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The present disclosure includes a fusion protein or molecule, called a “Macromolecule that depletes PLA2R-specific antibodies”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind target antigen-specific antibodies. The present disclosure also includes a method of depleting target antigen-specific antibodies from a patient by treating the patient with a macromolecule that targets PLA2R-specific antibodies having an antigen component configured to specifically bind the target antigen-specific antibodies.

Disclosed herein are methods of and compositions for identifying components of a molecular pathway, wherein the molecular pathway comprises a cell surface receptor. The method comprises use of ligand-coated nanoparticles and cells that internalize the ligand-coated nanoparticles. The methods allow analysis of a wide range of ligand- receptor complexes.

The invention provides a growth factor-dextran conjugate as well as a preparation method and application thereof, the growth factor-dextran conjugate consists of a growth factor and dextran, and is obtained by coupling an amino group of the growth factor and a hydroxyl group of the dextran through a chemical reaction; the growth factor-dextran conjugate can protect the growth factor to enhance the stability of the growth factor, reduce the degradation of the growth factor in vivo and prolong the in vivo half-life period of the growth factor; coupled dextran can be combined with a cell surface receptor to promote cellular uptake of growth factors and enhance the effective action concentration of the growth factors in cells, has good biocompatibility and biological safety, and has wide application in research and development of drugs for wound repair and / or treatment of neurodegenerative diseases.

Some aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or an RNAi oligonucleotide.

The present disclosure relates to engineered antigen-binding molecules that include engineered single domain antibody variable domains having substituted cysteine residues. The engineered single domain antibody variable domains may form covalent or non-covalent inter-chain associations. Engineered antigen-binding molecules may include single domain antibody variable domains that target and are capable of agonizing a cell surface receptor and may be used, for example, in methods of agonizing certain receptors.

This invention relates to bifunctional compounds and the use of such bifunctional compounds to reduce plasma levels of extracellular target molecules via lysosomal degradation. These bifunctional compounds have cell surface receptor ligands covalently linked to ligands capable of binding to extracellular target molecules (such as growth factors, cytokines, chemokines, hormones, neurotransmitters, capsids, soluble receptors, extracellular secretory proteins, antibodies, lipoproteins, exosomes, viruses, cell or plasma membrane proteins), wherein said cell surface receptors are associated with receptor-mediated endocytosis, including lysosomal degradation mediated by desialylate glycoprotein receptor (ASGPR) and lysosomal degradation mediated by mannose-6-phosphate receptor (M6PR). Pharmaceutical compositions comprising such bifunctional compounds and methods of treating diseases or disorders mediated by extracellular molecules using such bifunctional compounds are also provided herein.

This invention discloses a recombinant protein pPIC9K-17, its preparation method, and its applications, relating to the field of gene recombination technology. The recombinant protein pPIC9K-17 provided by this invention does not strictly follow the (Gly-X-Y)n triple helix repeat pattern of traditional collagen in its core structural unit. The repeating unit sequence includes a "GAIQ" sequence and a sequence containing collagen characteristics, possessing a certain rigid structural basis and containing receptor-binding or signal activation domains for specific growth factors. The direct tandem connection of multiple such units theoretically enables multivalent binding, enhancing affinity and signal activation efficiency with cell surface receptors, thus surpassing the biological functional limitations of single components (pure collagen or pure growth factors) or simple repeating structures. The recombinant protein of this invention not only effectively promotes the proliferation and migration of skin fibroblasts and accelerates collagen synthesis, but also shows clear efficacy in promoting hair regeneration (hair growth), and can be used to prepare products for skin repair and / or promoting hair regeneration.

Genetically engineered cells (e.g., HSPCs or T cells), such as hematopoietic stem cells, having one or more genetically edited genes of cell-surface proteins, and therapeutic uses thereof, either alone or in combination with immune therapy that targets the cell-surface protein(s).

This invention discloses a homogeneous polysaccharide from *Rhizoctonia solani* that exhibits antiviral activity against human cytomegalovirus in both the virus-cell binding stage and the post-virus invasion stage, along with its preparation method and applications. This polysaccharide is a homogeneous polysaccharide Ts1-1A extracted, isolated, and purified from the fruiting bodies of *Rhizoctonia solani*. *Rhizoctonia solani* homogeneous polysaccharide Ts1-1A is a novel heteropolymer containing partially branched chains, with its main chain consisting of →3)-α-Fuc p -(1→and→6)-α-Gal p -(1→ Composed in a 1:1 ratio, with T-α-Man branches p -(1→, connected to the 2nd and 3rd positions of the same Gal on the main chain, with an average of 2 branches replacing every 16 sugar residues in the main chain. During the viral attachment period, it can prevent the virus from adsorbing onto cell surface receptors by binding to the virus. At the same time, after entering the cell, it can inhibit viral replication through antioxidant effects, thereby exerting an antiviral effect.

The invention relates to the technical field of synthetic biology and lung cancer treatment, in particular to an aptamer-coupled engineering bacterium and application thereof in treatment of non-small cell lung cancer. Specifically, escherichia coli is taken as an original strain for the first time, a gene for coding the immune chemotactic factor CXCL9 is introduced into the original strain to obtain an engineering bacterium capable of expressing and secreting the immune chemotactic factor, the engineering bacterium is coupled with an aptamer, and the aptamer can specifically recognize and combine tumor-associated antigens or cell surface receptors. In addition, the invention also proves that the aptamer-coupled escherichia coli for expressing the immune chemotactic factor CXCL9 can specifically target solid tumors (especially non-small cell lung cancer) and inhibit the growth of the solid tumors in an organism for the first time through experiments in the organism.

This invention belongs to the field of food raw material science and discloses a chitosan-dextran nanopolysaccharide complex, its preparation method, and its applications. This invention proposes the use of an emulsifier. The combination of a low-concentration alkali and the emulsifier, along with a shortened processing time, preserves the natural properties of the complex while maximally removing related compounds such as proteins, lipids, fats, pigments, alkali-soluble dextran, and mineral compounds. This improves product purity while reducing CGC degradation during preparation and increasing removal efficiency. The chitosan-dextran nanopolysaccharide complex of this invention, due to its nano-sizing, provides optimal dispersibility in a hydrophilic environment, promoting better entry into the human body and interaction with cell surface receptors. It regulates the content of giant cells and the activity of T lymphocytes in vivo, effectively improving human immune regulation, and primarily inhibits tumors by enhancing the body's non-specific immune function.

The application belongs to the technical field of biological medicine, and particularly relates to a recombinant collagen repair solution and a preparation method and application thereof. The application comprises the following steps: preparation of a protein activity enhancer; preparation of a recombinant humanized collagen fiber sol; and photo-polymerization construction of a recombinant humanized collagen hydrogel. The application is modified by sulfate esterification of pollen of apiaceae polysaccharide, and is compounded with the recombinant humanized collagen. The application can not only form a stable complex with the positively charged collagen amino acid residues through electrostatic interaction, maintain the natural triple helix conformation, reduce the aggregation and denaturation of the collagen, and enhance the activity of the collagen, but also can assist the recombinant humanized collagen in activating the cell surface receptors, enhancing the adhesion and proliferation of the cells, thereby enhancing the epidermal regeneration capacity of the recombinant humanized collagen, effectively improving the bioavailability of the recombinant humanized collagen at the wound site, and improving the repair and treatment effect on the wounded skin.

The invention discloses an extracellular vesicle targeting pericerebral cells and a medicine, and relates to the technical field of biological medicines. According to the extracellular vesicles targeting the pericerebral cells, the extracellular vesicles can be delivered to the pericerebral cells in a targeted mode through the targeting ligand modified on the surface of the extracellular vesicles and the cell surface receptor capable of being specifically combined with the pericerebral cells, and a new delivery tool and therapeutic drug selection are provided for treatment of central nervous system related diseases.

Expression cassettes comprising FOXP3 proteins, chimeric receptors, and / or cell surface receptors are provided. Also provided herein are Treg cells comprising the expression cassettes and methods of use.

The present application relates to a compound or a pharmaceutically acceptable salt and / or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and / or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and / or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and / or killing target cells. For example, the compound includes a compound of Formula I

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Provided are chimeric cell surface receptors comprising an extracellular domain of a cell surface receptor and an intracellular domain of a different cell surface receptor. In certain embodiments, a chimeric cell surface receptor of the present disclosure comprises an extracellular domain of a tumor necrosis factor receptor (TNFR) and an intracellular domain of a different TNFR or a receptor other than a TNFR. According to other embodiments, a chimeric cell surface receptor of the present disclosure comprises an extracellular domain of an interleukin receptor (ILR) and an intracellular domain of a different ILR or a receptor other than an ILR. Also provided are cells (e.g., immune effector cells) that express a chimeric cell surface receptor of the present disclosure. Also provided are methods of using such cells to treat a condition (e.g., cancer, infection, and / or the like) in a subject in need thereof.

The invention provides a feed premix for increasing intramuscular fat content of livestock and poultry and application of the feed premix. The premix comprises the following components: 1-10% of a quercetin metal chelate; 2 to 15% of tea polyphenol; 20-50% of soybean phospholipid; and the balance of a carrier and a diluent. The mass ratio of the quercetin metal chelate to the tea polyphenol to the soybean phospholipid is (1-2): (2-4): (10-20). Through a synergistic system of the quercetin metal chelate, the tea polyphenol and the soybean phospholipid, targeted efficient deposition of intramuscular fat is achieved, the meat quality is improved, and body fat distribution is not affected; the chelation of quercetin and divalent metal ions changes the molecular polarity of quercetin and improves the water solubility, the quercetin is not easily degraded by acid, alkali and enzyme in gastrointestinal tracts of livestock and poultry, the stability is obviously enhanced, and the in-vivo action time is prolonged; meanwhile, the metal ions can be used as a bridge to promote the combination of quercetin and a cell surface receptor or enzyme, improve the enrichment degree of quercetin in muscle tissue preadipocytes and enhance the regulation efficiency of a fat metabolism signal channel.

The present disclosure relates to engineered IgG molecules having an IgM Cμ2 domain substituted for all or a portion of an IgG hinge region. Engineered IgG molecules may include one or more targeting moieties that are capable of agonizing a cell surface receptor and may be used, for example, in methods of agonizing certain receptors.

Described herein are compositions and techniques related to the generation and therapeutic applications of engineered extracellular vesicles. In some embodiments, the engineered extracellular vesicles are vesicles (i.e., exosomes) comprising at least one engineered fusion polypeptide that further comprises a vesicle targeting domain, a scaffold linker domain, and a signaling domain (i.e., a multi-effector signaling domain), wherein the signaling domain targets and interacts with a biological target, such as a cell surface receptor. The engineered fusion proteins can be expressed tissue in a genetic vector construct, in mammalian cells, in which a vesicle targeting domain is anchored on an extracellular vesicle, such as an exosome, thereby presenting its linked multi-effector signaling domain that can deliver a signal to a target cell. The engineered extracellular vesicles have biophysical and biochemical characteristics indicative of the extracellular vesicles, allowing for rapid deployment and large scale production. Importantly, this strategy may allow for kinetically advantageous signal generation as well as signal propagation to target cells.

The invention discloses a pMHC binding agent and application thereof. The antigen peptide-major histocompatibility complex binding agent comprises four RNA molecules, wherein the first RNA molecule comprises an antigen peptide, a DRB1 * 13: 02 beta chain, a mouse I-Eb binding segment and nucleic acid molecules coded by CD28 and CD3 zeta proteins of transmembrane and intracellular segments; the second RNA molecule comprises CMV, CD74, an antigen peptide and a nucleic acid molecule coded by a red visible spectrum fluorescent protein; the third RNA molecule comprises CD4 and a nucleic acid molecule coded by a T cell surface receptor binding region peptide sequence; and the fourth RNA molecule comprises mCD40L and a nucleic acid molecule coded by a binding peptide fragment for recognizing pMHC. According to the present invention, the antigen peptide-major histocompatibility complex II type molecule and the T cell surface receptor can be efficiently and specifically combined so as to promote the activation of the target cell surface receptor so as to achieve the efficient autoimmune reaction;

The present application relates to a compound or a pharmaceutically acceptable salt and / or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and / or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and / or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and / or killing target cells. For example, the compound includes a compound of Formula I

The present application relates to the biomedical technology field, especially to an immune regulation chiral material and its preparation method and application, the immune regulation chiral material is self-assembled by immune active component and delivery carrier.Immune active component is selected from chiral peptide modified distearoyl phosphatidylethanolamine-polyethylene glycol, and the chiral peptide is connected by 6-10 D-alanine monomers by amide bond.The material can realize precise targeting of target cells by specific stereoscopic recognition of chiral peptide and immune cell surface receptors, and reduce non-specific effects on normal tissues;Delivery carrier represented by lipid nanoparticles can effectively protect chiral peptide from in vivo enzymolysis, improve its circulating stability, and natural carriers such as exosomes can enhance the biocompatibility and tissue penetration of the material, providing a new strategy for immunotherapy of diseases such as tumors, and being expected to be applied to clinical treatment as a new immunotherapy drug.

The present disclosure includes a fusion protein or molecule, called a "Macromolecule that depletes ADAMTS13-specific antibodies'; including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind target antigen-specific antibodies. The present disclosure also includes a method of depleting target antigen-specific antibodies from a patient by treating the patient with a macromolecule that targets ADAMTS13-specific antibodies having an antigen component configured to specifically bind the target antigen-specific antibodies.